These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23087409)

  • 1. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.
    Veal GJ; Errington J; Rowbotham SE; Illingworth NA; Malik G; Cole M; Daly AK; Pearson AD; Boddy AV
    Clin Cancer Res; 2013 Jan; 19(2):469-79. PubMed ID: 23087409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.
    Gota V; Chinnaswamy G; Vora T; Rath S; Yadav A; Gurjar M; Veal G; Kurkure P
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):763-8. PubMed ID: 27541143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.
    Veal GJ; Cole M; Errington J; Pearson AD; Foot AB; Whyman G; Boddy AV;
    Br J Cancer; 2007 Feb; 96(3):424-31. PubMed ID: 17224928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma.
    Veal G; Rowbotham S; Boddy A
    Therapie; 2007; 62(2):91-3. PubMed ID: 17582307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.
    Matthay KK
    Clin Cancer Res; 2013 Jan; 19(2):311-3. PubMed ID: 23209029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
    Sonawane P; Cho HE; Tagde A; Verlekar D; Yu AL; Reynolds CP; Kang MH
    Br J Pharmacol; 2014 Dec; 171(23):5330-44. PubMed ID: 25039756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
    Villablanca JG; Khan AA; Avramis VI; Seeger RC; Matthay KK; Ramsay NK; Reynolds CP
    J Clin Oncol; 1995 Apr; 13(4):894-901. PubMed ID: 7707116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma.
    Hoemberg M; Schwenzfeur R; Berthold F; Simon T; Hero B
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29374. PubMed ID: 34569150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
    Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
    Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
    Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation.
    Khan AA; Villablanca JG; Reynolds CP; Avramis VI
    Cancer Chemother Pharmacol; 1996; 39(1-2):34-41. PubMed ID: 8995497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
    Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
    Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.
    Ponthan F; Borgström P; Hassan M; Wassberg E; Redfern CP; Kogner P
    Med Pediatr Oncol; 2001 Jan; 36(1):127-31. PubMed ID: 11464864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy.
    Kohler JA; Imeson J; Ellershaw C; Lie SO
    Br J Cancer; 2000 Nov; 83(9):1124-7. PubMed ID: 11027423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
    Matthay KK; Villablanca JG; Seeger RC; Stram DO; Harris RE; Ramsay NK; Swift P; Shimada H; Black CT; Brodeur GM; Gerbing RB; Reynolds CP
    N Engl J Med; 1999 Oct; 341(16):1165-73. PubMed ID: 10519894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma.
    Shah N; Wang J; Selich-Anderson J; Graham G; Siddiqui H; Li X; Khan J; Toretsky J
    Clin Cancer Res; 2014 Aug; 20(16):4400-12. PubMed ID: 24947929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology.
    Bauters TG; Laureys G; Van de Velde V; Benoit Y; Robays H
    Int J Clin Pharm; 2011 Aug; 33(4):597-8. PubMed ID: 21544558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
    Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
    Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.